A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 30
- 试验地点
- 20
- 主要终点
- Part 1 - Incidence of Treatment Emergent Adverse Events (TEAEs)
研究概览
简要总结
This study is an open-label, multi-center, dose-escalation, dose expansion study in adult subjects with advanced solid tumors. The study will evaluate the safety, tolerability, PK, and preliminary anti-tumor efficacy of SM08502 administered orally (PO), once daily (QD), following a 5 days on 2 days off treatment schedule in combination with chemotherapy or hormonal therapy. Alternative dosing schedules may be explored in Part 1 if necessary. The recommended Part 2 dose and schedule for each combination will then be further evaluated in the Part 2 expansion.
Dosing will occur in 21- or 28-day cycles (depending on the combination partner) and treatment with SM08502 will continue within each subject unless treatment is discontinued due to toxicity, disease progression, initiation of a new anti-neoplastic therapy, withdrawal of consent, the Sponsor terminates the study, or the subject no longer meets retreatment criteria.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Part 1 - Subjects with advanced and/or metastatic solid tumors. Histologic or cytologic confirmation of malignancy must have been obtained at diagnosis. The tumor types include:
- •i. CRPC - Subjects with progressive disease in the setting of medical or surgical castration (i.e., castration-resistant prostate cancer).
- •ii. NSCLC (adenocarcinoma subtype) - Subjects with no targetable mutations must have received a platinum-containing doublet chemotherapy regimen and a checkpoint inhibitor (either in combination or monotherapy, if indicated) and have progressed. Subjects with targetable mutations/alterations such as EGFR, ALK, or NTRK must have received prior targeted therapy and have progressed.
- •iii. CRC - Subjects must have received one prior line of standard chemotherapy such as FOLFOX +/- a VEGF-inhibitor and have progressed or are intolerant of oxaliplatin based regimens.
- •Part 2 - Subjects with advanced and/or metastatic solid tumors. Histologic or cytologic confirmation of malignancy must have been obtained at diagnosis. The tumor types include:
- •i. CRPC - Subjects with progressive disease in the setting of medical or surgical castration (i.e., castration- resistant prostate cancer). Subjects who have not received chemotherapy, are not candidates for chemotherapy, or refuse chemotherapy are eligible (Arm A). Subjects who have received chemotherapy are eligible (Arm B), however, more than 2 prior lines of chemotherapy in any setting are excluded.
- •ii. NSCLC (adenocarcinoma subtype) - Subjects with no targetable mutations must have received a platinum-containing doublet chemotherapy regimen and a checkpoint inhibitor (either in combination or monotherapy, if indicated) and have progressed. Subjects with targetable mutations/alterations such as EGFR, ALK, NTRK must have received prior targeted therapy and have progressed.
- •iii. CRC - Subjects must have received one prior line of standard chemotherapy such as FOLFOX +/- either a VEGF-inhibitor or EGFR inhibitor (if indicated) and have progressed or are intolerant of oxaliplatin based regimens.
- •Male or female subjects ≥ 18 years of age.
- •3.0 Measurable or evaluable disease per RECIST 1.1 (Part 1). For Part 2, at least one measurable lesion per RECIST 1.1 that has not been previously irradiated. In CRPC subjects (Parts 1 and 2) without measurable disease per RECIST 1.1, a PSA that is concordant with clinical disease progression (rising) is eligible. A PSA value of 2 ng/ml or greater is required for study entry for those without measurable disease.
- •Subjects must have archived tumor specimens available for analysis Otherwise, a fresh tumor biopsy will be required at study entry.
- •5.0.. Subjects must have recovered (i.e., Grade 1 [or better] based on CTCAE v5.0) from all toxicity associated with previous chemotherapy, targeted therapy, experimental therapy, biological therapy, immuno-oncology therapy, surgery, radiotherapy, or other locoregional therapy.
- •The following intervals must elapse between end of last treatment and receiving the first dose of SM08502:
- •Chemotherapy: 3 weeks.
- •Mitomycin C or a nitrosourea: 6 weeks.
- •Radiotherapy: 3 weeks.
- •Major surgery: 6 weeks.
- •Targeted therapy, including monoclonal antibodies and immuno-oncology therapies: 4 weeks or 5 half-lives, whichever is shortest.
- •Subjects must meet the following laboratory criteria at Screening for study entry:
- •Hepatic function: serum total bilirubin ≤ 1.5x upper limit of normal (ULN), AST/ALT ≤ 2.5x ULN. For subjects with Gilbert's syndrome, serum total bilirubin ≤ 3x ULN.
- •Renal function: measured or calculated creatinine clearance via Cockcroft-Gault formula >35 mL/min.
- •Hematology: absolute neutrophil counts ≥ 1500/mm3, platelet counts ≥ 100,000/mm3, hemoglobin ≥ 9.0 g/dL.
- •Coagulation: prothrombin time (PT) and partial thromboplastin time (PTT) ≤ 1.5x ULN.
- •Eastern Cooperative Oncology Group (ECOG) performance status ≤
- •Life expectancy > 3 months.
- •Subjects must have no uncontrolled intercurrent illness.
- •10.0 Subjects must have the ability to swallow and retain oral medication.
- •11.0 Subjects must be willing to sign and provide informed consent and be capable of giving informed consent in accordance with the Institutional Review Board (IRB) / Ethics Committee (EC) policy.
排除标准
- •Women who are pregnant or lactating.
- •Women of childbearing potential (WOCBP) must agree to follow the contraceptive guidelines as outlined in protocol.
- •Men of reproductive potential must agree to follow the contraceptive guidelines as outlined in protocol.
- •Subjects with a QTc (Fridericia's) prolongation > CTCAE v5.0 Grade 1 (>480 msec) at Screening.
- •Subjects with clinically significant ventricular tachycardia (VT), atrial fibrillation (AF), ventricular fibrillation (VF), second- or third-degree heart block.
- •Subjects with myocardial infarction (MI) within 1 year, Class II-IV congestive heart failure (CHF) per New York Heart Association (NYHA) classification, or clinically significant coronary artery disease (CAD)..
- •Subjects with active infection (e.g., requiring antibiotic therapy).
- •Organ transplant recipients.
- •Subjects with untreated, progressing, or known symptomatic brain metastasis.
- •Subjects with a second malignancy unless adequately treated with no recurrence for 3 years. Subjects with a history of previous or recent adequately treated basal cell or squamous cell carcinoma of the skin, or carcinoma in situ of any source are eligible.
- •Subjects with known hypersensitivity to any excipients in the study drug formulation.
- •Subjects with active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of SM08502 per Investigator's opinion.
- •Subjects with known active human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection.
- •Subjects considered by the Investigator to be unsuitable for the study for any other reason.
- •Subjects with chronic liver disease or dysfunction and a Child-Pugh score of B or C.
研究组 & 干预措施
CRC (Colorectal Cancer) - SM08502 + FOLFIRI/Panitumumab
Part 1 (dose escalation cohorts) will evaluate SM08502 in subjects with advanced CRC.
Subjects will receive increasing doses of SM08502 with fixed doses of FOLFIRI plus panitumumab ( RAS wild type tumors) or with fixed doses of FOLFIRI (RAS mutant tumors)
Escalation will follow a 3+3+3 design within each cohort.
Part 2 will further evaluate the recommended dose and schedule of SM08502. Subjects that have RAS wild type tumors will receive FOLFIRI and panitumumab with SM08502 (n=15). Subjects that have RAS mutant tumors will receive FOLFIRI with SM08502 (n=15).
干预措施: FOLFIRI Protocol (Drug)
CRC (Colorectal Cancer) - SM08502 + FOLFIRI/Panitumumab
Part 1 (dose escalation cohorts) will evaluate SM08502 in subjects with advanced CRC.
Subjects will receive increasing doses of SM08502 with fixed doses of FOLFIRI plus panitumumab ( RAS wild type tumors) or with fixed doses of FOLFIRI (RAS mutant tumors)
Escalation will follow a 3+3+3 design within each cohort.
Part 2 will further evaluate the recommended dose and schedule of SM08502. Subjects that have RAS wild type tumors will receive FOLFIRI and panitumumab with SM08502 (n=15). Subjects that have RAS mutant tumors will receive FOLFIRI with SM08502 (n=15).
干预措施: Panitumumab (Drug)
CRC (Colorectal Cancer) - SM08502 + FOLFIRI/Panitumumab
Part 1 (dose escalation cohorts) will evaluate SM08502 in subjects with advanced CRC.
Subjects will receive increasing doses of SM08502 with fixed doses of FOLFIRI plus panitumumab ( RAS wild type tumors) or with fixed doses of FOLFIRI (RAS mutant tumors)
Escalation will follow a 3+3+3 design within each cohort.
Part 2 will further evaluate the recommended dose and schedule of SM08502. Subjects that have RAS wild type tumors will receive FOLFIRI and panitumumab with SM08502 (n=15). Subjects that have RAS mutant tumors will receive FOLFIRI with SM08502 (n=15).
干预措施: SM08502 (Drug)
NSCLC (Non-Small Cell Lung Cancer) - SM08502 + Docetaxel
Part 1 (dose escalation cohorts) will evaluate SM08502 in subjects with advanced NSCLC.
Subjects will receive increasing doses of SM08502 with fixed doses of docetaxel to determine the MTD and recommended Part 2 dose and schedule.
Escalation will follow a 3+3+3 design within each cohort.
Part 2 will further evaluate the recommended dose and schedule of SM0850 in subjects with advanced NSCLC. Approximately 20 subjects will be enrolled.
干预措施: SM08502 (Drug)
CRPC (Castration Resistant Prostate Cancer) - SM08502 + Abiraterone/Prednisone
Part 1 (dose escalation cohorts) will evaluate SM08502 in subjects with advanced CRPC.
Subjects will receive increasing doses of SM08502 with fixed doses of Abiraterone/Prednisone to determine the MTD and recommended Part 2 dose and schedule.
Escalation will follow a 3+3+3 design within each cohort.
Part 2 will further evaluate the recommended dose and schedule of SM08502 in subjects with advanced CRPC. Approximately 20 subjects will be enrolled.
干预措施: SM08502 (Drug)
CRPC (Castration Resistant Prostate Cancer) - SM08502 + Abiraterone/Prednisone
Part 1 (dose escalation cohorts) will evaluate SM08502 in subjects with advanced CRPC.
Subjects will receive increasing doses of SM08502 with fixed doses of Abiraterone/Prednisone to determine the MTD and recommended Part 2 dose and schedule.
Escalation will follow a 3+3+3 design within each cohort.
Part 2 will further evaluate the recommended dose and schedule of SM08502 in subjects with advanced CRPC. Approximately 20 subjects will be enrolled.
干预措施: Abiraterone (Drug)
CRPC (Castration Resistant Prostate Cancer) - SM08502 + Abiraterone/Prednisone
Part 1 (dose escalation cohorts) will evaluate SM08502 in subjects with advanced CRPC.
Subjects will receive increasing doses of SM08502 with fixed doses of Abiraterone/Prednisone to determine the MTD and recommended Part 2 dose and schedule.
Escalation will follow a 3+3+3 design within each cohort.
Part 2 will further evaluate the recommended dose and schedule of SM08502 in subjects with advanced CRPC. Approximately 20 subjects will be enrolled.
干预措施: Prednisone (Drug)
NSCLC (Non-Small Cell Lung Cancer) - SM08502 + Docetaxel
Part 1 (dose escalation cohorts) will evaluate SM08502 in subjects with advanced NSCLC.
Subjects will receive increasing doses of SM08502 with fixed doses of docetaxel to determine the MTD and recommended Part 2 dose and schedule.
Escalation will follow a 3+3+3 design within each cohort.
Part 2 will further evaluate the recommended dose and schedule of SM0850 in subjects with advanced NSCLC. Approximately 20 subjects will be enrolled.
干预措施: Docetaxel (Drug)
结局指标
主要结局
Part 1 - Incidence of Treatment Emergent Adverse Events (TEAEs)
时间窗: Consent date to 28 days after the last dose of study treatment
As measured by NCI CTCAE version 5.0.
Part 1 - Maximum tolerated dose (MTD) of SM08502 when combined with standard of care agents.
时间窗: DLT period of 21 or 28 days per dose level depending on cycle length
Based on frequency and severity of dose-limiting toxicities (DLTs).
Part 1 - Blood samples for measurement of the plasma levels of SM08502 and its metabolite
时间窗: Sample collection timepoints: Cycle1 (Day1 (0,2,4,6, hrs), Day2, Day8, Day15, Day22) Cycle 2 (Day1, Day2) Cycle3-5 (Day1) and EOT. Each cycle is 21 or 28 days depending on tumor type.
Area under the plasma concentration time curve (AUC) from zero to the last measurable concentration: AUClast for SM08502 and its metabolite SM08955.
Part 1 - Plasma drug concentration
时间窗: Sample collection timepoints: Cycle1 (Day1 (0,2,4,6, hrs), Day2, Day8, Day15, Day22) Cycle 2 (Day1, Day2) Cycle3-5 (Day1) and EOT. Each cycle is 21 or 28 days depending on tumor type.
Maximum steady-state plasma drug concentration (Cmaxss) during a dosage interval.
Part 2 - Incidence of Safety and tolerability of SM08502
时间窗: Consent date to 28 days after the last dose of study treatment
As measured by treatment emergent adverse events (TEAEs) as measured by NCI CTCAE version 5 from subjects treated at the recommended Part 2 dose and schedule.
Part 2 - Objective response rate
时间窗: Approximately 5 years
Using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or Prostate Cancer Working Group 3 Criteria (PCWG3) where appropriate.
次要结局
- Part 1 - Objective Response rate(Approximately 5 years)
- Part 2 - Blood samples for measurement of the plasma levels of SM08502 and its metabolite(Sample collection timepoints: Cycle1 (Day1 (0,2,4,6, hrs), Day2, Day8, Day15,) Cycle 2-5 (Day1). Each cycle is 21 or 28 days depending on tumor type.)